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BACKGROUND: Mucoepidermoid carcinoma (MEC) shows differences in biological behaviour depending mainly on its histological
grade. High-grade tumours usually have an aggressive biological course and they require additional oncological treatment after
surgery.
METHODS: In a series of 43 MECs of the salivary glands, we studied the epidermal growth factor receptor (EGFR) gene by using dual-
colour chromogenic in situ hybridisation (CISH). Moreover, we assessed the protein expressions of the EGFR and the activated
extracellular signal-regulated kinases (pERK1/2) by using immunohistochemistry. These results were correlated with the histological
grade of the tumours and the outcome of the patients.
RESULTS: The CISH study demonstrated a high-EGFR gene copy number, with balanced chromosome 7 polysomy, in 8 out of 11 high-
grade MECs (72.7%), whereas 27 low-grade and 15 intermediate-grade tumours had a normal EGFR gene copy number (Po0.001).
The EGFR gene gains correlated with disease-free interval (P¼0.003) and overall survival of the patients (P¼0.019). The EGFR
protein expression had a significant correlation with the histological grade of the tumours but not with the outcome of the patients.
The pERK1/2 expression correlated with histological grade of tumours (Po0.001), disease-free interval (P¼0.004) and overall
survival (P¼0.001).
CONCLUSIONS: The EGFR/ERK pathway is activated in high-grade MECs with aggressive behaviour. Patients with these tumours who
require oncological treatment in addition to surgery could benefit from EGFR and mitogen-activated protein kinase pathway
inhibitors.
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Mucoepidermoid carcinoma (MEC) is the most frequent malignant
tumour that originates in the major and minor salivary glands, and
represents about one third of all malignant salivary gland tumours
(Spiro, 1986; Goode and El-Naggar, 2005; Ellis and Auclair, 2008).
It is a heterogeneous neoplasm that may present different
biological behaviour, depending mainly on the histological grade
of the tumour (Goode et al, 1998; Goode and El-Naggar, 2005; Ellis
and Auclair, 2008; Nance et al, 2008). Surgical resection is the
standard treatment for all grades of MEC. Radiotherapy after wide
surgical excision of the tumour is recommended for high-grade
MECs. Lymphadenectomy and adjunvant external beam radio-
therapy are indicated when cervical metastases are present.
Chemotherapy is indicated in the treatment of metastatic disease
and in the palliation of locoregional disease not amenable to either
salvage surgery or radiation therapy (Agulnik and Siu, 2004; Nance
et al, 2008). Low-grade MECs usually do not recur; most patients
are cured after surgery and the 5-year survival rate is 76–95%.
Conversely, high-grade MECs are aggressive neoplasms that
frequently have an infiltrative pattern of growth, recur and even
metastasize, and their 5-year survival rate is 30–50% (Goode et al,
1998; Nance et al, 2008).
To date, clinical trials using targeted therapies on salivary gland
tumours are scarce, probably because of the low number of these
cases in each institution. Only one phase II study of Herceptin
(Trastuzumab) with disappointing results in patients with
advanced salivary gland tumours overexpressing HER2/neu has
been published (Haddad et al, 2003). Incomplete clinical trials
using epidermal growth factor receptor (EGFR) antagonists have
been performed on patients with salivary gland cancer. Moreover,
studies on the oncogenetic pathways in salivary gland MECs
predictive of response to targeted therapies are scarce and
incomplete. In recent years, strategies against the EGFR family
and the mitogen-activated protein kinase (MAPK) signalling
pathway have received special attention in the treatment of cancer.
The EGFR family, including the four distinct receptors
EGFR/ErbB1, HER2/cerbB2, HER3/CerbB3 and HER4/ErbB4, has
been identified as a potential therapeutic target in solid tumours.
The EGFR/ErbB1 is a gene located on chromosome 7p12 and has
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semerged as a significant factor in the development and growth of
many types of cancer, playing an important role in cancer-cell
proliferation, angiogenesis and metastasis. This gene encodes a
170-kDa membrane glycoprotein that can be activated by
phosphorylation and induce a downstream signalling transduction
cascade. A major signalling route of the EGFR is the Ras-Raf-
MAPK pathway (Klapper et al, 2000). Activation of Ras initiates a
multistep phosphorylation cascade that leads to the activation of
MAPKs. The MAPK extracellular signal-regulated kinases ERK1/2
are the best characterised and are most strongly associated with
human cancer. The ERK1/2 are activated by dual phosphorylation
on a tyrosine and a threonine residue by dual-specificity kinases,
and subsequently regulate cell transcription and have been linked
to proliferation, survival and transformation (Lewis et al, 1998).
The EGFR antagonists are included in treatment protocols of
advanced stages of non-small cell carcinoma of the lung, colorectal
cancer and head and neck squamous cell carcinoma (Ciardello and
Tortora, 2008). In head and neck tumours, EGFR can be abnormally
activated and protein overexpression by the neoplastic cells is
frequently detected by immunohistochemistry (Nicholson et al,
2001; Grandis and Sok, 2004). However, EGFR amplifications are not
frequent and EGFR activating mutations are very rare (Kalyankrishna
and Grandis, 2006). The EGFR overexpression has been correlated
with poor prognosis in head and neck cancer (Kalyankrishna and
Grandis, 2006). To date, several clinical trials have been carried out
to identify the molecular characteristics of the tumours predictive
of response to EGFR antagonists. The EGFR activating mutations
and increased EGFR gene copy number identify the most sensitive
population in these tumours (Cappuzzo et al, 2005; Hirsch et al,
2005; Tsao et al, 2005; Sartore-Bianchi et al, 2007). In most MECs
of the salivary gland, the EGFR protein is overexpressed (Gibbons
et al, 2001; Shang et al, 2007), but EGFR activating mutations are
extremely rare (Han et al, 2008; Dahse and Kosmehl, 2008; Dahse
et al, 2009). However, studies on the EGFR gene copy number have
not been performed before in a series of salivary gland MECs.
In our previous studies, we saw that high-grade MECs with
aggressive course differ molecularly from low-grade tumours. These
high-grade tumours overexpress the oncogenic glycoprotein MUC1
(Alos et al, 2005; Handra-Luca et al, 2005). MUC1 acts as a proto-
oncogene that interacts with EGFR and correlates with MAPK
activation in mouse models (Schroeder et al, 2001) and inhibits the
ligand-mediated ubiquitinisation and degradation of EGFR in vitro
(Pochampalli et al, 2007). Moreover, the expression of ERK1/2
MAPKs has been related to aggressive tumour behaviour in MECs of
the salivary glands (Handra-Luca et al,2 0 0 3 ) .W et h e r e f o r e
hypothesised that histological high-grade MECs, which have a
clinically aggressive course, may harbour EGFR protein over-
expression and high-EGFR gene copies linked to aggressive tumour
biology. To investigate this, we studied the EGFR gene by using
chromogenic in situ hybridisation (CISH) with a dual-colour probe,
in a series of 43 MECs. This new technique obtains the same results
as fluorescence in situ hybridisation (FISH) and offers potential
advantages over FISH to detect gene copy number, including the
ability to distinguish between areas of tumour and normal tissue.
In addition to genetic analysis, the immunohistochemical study
of the EGFR protein was performed and activated ERK1/2 were
assessed by using an antibody specific for the dually phosphory-
lated and activated ERK1 and ERK2 (MAPK phospho-p44/42).
These molecular studies have been correlated with the histological
characteristics of the tumours and the follow-up of the patients.
MATERIALS AND METHODS
Selection of cases
Forty-three MECs diagnosed at the Department of Pathology
of the Hospital Clinic, and Hospital Princeps d’Espanya, Bellvitge,
University of Barcelona, from 1996 until 2005, were reviewed.
The medical records were obtained from patients’ files in the
Departments of Otorhinolaryngology and Maxillofacial Surgery.
The study was approved by the Local Ethical Committee and
patients gave their informed consent. At diagnosis, the tumours
were staged according to the American Joint Committee on Cancer
(Sobin and Wittekind, 2002). All patients underwent primary
surgery as standard treatment. Lymph node dissection was
performed only in cases with lymph node metastases. Full-dose
radiotherapy was applied after tumour excision with positive
margins, when lymph node metastases were assessed, and in
locoregional recurrences. Chemotherapy with cisplatin was added
for palliative purposes, in patients with lymph node metastases
(N2 or N3) and in cases with tumoural persistence after surgery
and resistance to radiotherapy.
Histological grading of MECs
Haematoxylin-eosin and alcian blue-stained slides and paraffin
wax-embedded material were available for all cases. The MECs
were graded following the 2005 World Health Organization
Classification of Tumours (Goode and El-Naggar, 2005).
CISH and immunohistochemistry
Representative paraffin wax blocks were selected from each of the
43 cases for CISH and immunohistochemistry.
The CISH was performed on a 4-mm section of each tumour that
was deparaffined in two changes of xylene and three washes of
degraded ethanol for 3min each. The slides were pretreated with
CISH pretreatment buffer (Dako, Carpinteria, CA, USA) and
heated to 921C, and then rinsed with distilled water. The tissues
were digested for 10min with pepsin digestion solution (Dako) at
room temperature, washed twice in distilled water for 5min each,
dehydrated in 70, 85 and 96% alcohol for 2min each and dried.
A measure of 10ml of dual-colour EGFR Spectrum-red/CEP7
Spectrum-blue probe (Dako) were applied to each slide. Sections
were covered with coverslips and denatured on a hot plate at 821C
for 5min. Hybridisation was done overnight at 371C. Then the
slides were washed in 2 SSC at 731C for 2min and three times in
distilled water. Then the sections were blocked with H2O2 in
absolute methanol and incubated with a blocking reagent for
10min at room temperature. The hybridisation signals were
detected after sequential incubations with anti-mouse anti-DIG
(60min at room temperature), polymerised horseradish pero-
xidase anti-mouse antibody (60min) and 3,3-diaminobenzedine
(DAB). The sections were counterstained with haematoxylin.
Immunohistochemical studies were carried out using the
automated immunohistochemical system TechMate 500 (Dako),
and the EnVision system (Dako). Briefly, 4mm sections were
deparaffinised and hydrated using graded alcohols and water. For
antigen retrieval, an autoclave pretreatment at 1201C for 5min was
performed. Peroxidase was blocked for 7.5min in ChemMate
peroxidase-blocking solution (Dako). The slides were incubated
with the primary antibodies for 30min and washed in ChemMate
buffer solution (Dako). The peroxidase labelled polymer was then
applied for 30min. After being washed in ChemMate buffer
solution, the slides were incubated with DAB substrate chromogen
solution, washed in water, counterstained with haematoxylin,
washed, dehydrated and mounted. The primary antibodies used in
the study were: EGFR (Dako; dilution 1:100) and pERK1/2
(Phospho-p44/42; Thr202/Tyr204) (Cell Signaling Technology,
Beverly, MA, USA; dilution 1:50). Appropriate positive and
negative controls were used.
The CISH and immunohistochemical results were evaluated by
two independent observers (BL and LA). For CISH evaluation, a
light microscope under a  40 objective was used. A total number
of 100 tumoural cells were evaluated. The centromeric blue signal
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sand the EGFR red signal in each cell were counted and the
proportion centromeric/EGFR signal number was calculated. The
cases were considered normal if two blue and two red signals were
visualised in each nuclear cell. Polysomy was considered when X3
blue and red signals (in equal number) were seen in each nucleus.
The EGFR amplification was defined as red signals 41.5 blue
signals.
The immunostain for EGFR was evaluated: 0, no positive cells;
1þ, low discontinuous membrane staining; 2þ, unequivocal
membrane staining with moderate intensity and 3þ, strong and
complete membrane staining. Only cases with 2þ and 3þ
staining patterns were considered positive. The pERK1/2 showed
nuclear positivity. For analytical purposes, positivity for EGFR and
pERK1/2 was considered when X10% of tumour cells were
positive. High-pERK1/2 expression was considered when X30%
of positive cells were detected.
Statistical analysis
The continuous clinical variables considered were follow-up and
age (median and range were calculated). Overall survival was
calculated from diagnosis to the death of the patient or loss of
follow-up. Disease-free interval was the time from surgical excision
of the tumour to the first recurrence or metastasis. Both overall
survival and disease-free interval were analysed by the Kaplan–
Meier method. The categorical clinical variables were gender
(female/male), location of tumours (parotid/submaxillary/minor
salivary gland) and stage (I/II/III/IV). The categorical histological
variables considered were histological grade (1/2/3) and molecular
results: EGFR protein expression (positive/negative), EGFR gene
copy (normal/polysomy) and ERK1/2 expression (430% of
positive cells/o30% of positive cells). Fisher’s exact test was used
for comparison between qualitative variables and Student’s t-test
and ANOVA were applied for quantitative variables according to
the application conditions. All tests were two sided. Differences
were analysed by the log-rank method. Differences were con-
sidered to be statistically significant with an a risk of 0.05.
RESULTS
Clinicopathological characteristics of the patients
The clinicopathological characteristics of the patients at diagnosis,
the treatment details and outcome are summarised in Table 1.
After a median follow-up of 62 months, 33 (76.8%), 6 (13.9%)
and 4 (9.3%) patients were alive and disease free, alive with disease
and died of disease, respectively. The median disease-free interval
was 96 months (range 0–159 months). Relapses occurred in 19
(44.1%) patients: in 14 (32.6%) patients, a local tumoural
recurrence took place, and in 5 (11.6%) patients, there was lymph
node metastasis.
The statistical associations of the disease-free interval and
overall survival with histological grade of tumours and molecular
results are expressed in Table 2. Patients with high-grade tumours
had shorter disease-free interval (P¼0.001) and overall survival
(P¼0.001) than those with low- and intermediate-grade tumours.
EGFR gene analysis
Eight cases (18.6%) had chromosome 7 polysomy. In these cases,
there were 42 signals of both centromere and EGFR signals in
over 70% of cells, but the relationship between both signals was
1:1. In two cases there were 3 signals (low polysomy) and in six
cases there were 43 signals (high polysomy). No cases with EGFR
amplification were detected. All of the eight cases with chromo-
some 7 polysomy were high-grade MECs, whereas the rest of the
tumours (27 low grade, 5 intermediate grade and 3 high grade)
showed a normal pattern of expression (Po0.001). Chromosome 7
polysomy was associated with shorter disease-free interval
(P¼0.003) and overall survival (P¼0.019) (Figure 1).
EGFR and pERK1/2 protein expression
The EGFR protein expression was positive in 34 tumours (79%).
All cases with chromosome 7 polysomy showed expression of the
EGFR protein (Po0.001). These cases showed positivity in 460%
of tumoural cells. High-EGFR protein expression was associated
with high-histological grade of tumour (Po0.001, ANOVA), but it
Table 1 Clinicopathological characteristics of the patients at diagnosis,
treatment details and outcome
Characteristic No. of cases (%)
Patient number 43
Age (years)
Median (range) 53 (4–82)
Gender
Female 23 (53.5%)
Male 20 (46.5%)
Tumour location
Parotid gland 22 (51%)
Minor salivary gland 15 (35%)
Submaxillary gland 6 (14%)
Histological grade of tumours
Low grade 27 (63%)
Intermediate grade 5 (11.5%)
High grade 11 (25.5%)
Stage
I 19 (44%)
II 6 (14%)
III 3 (7%)
IV 15 (35%)
Primary treatment
Radical surgery 36 (83.7%)
Surgery and full-dose radiotherapy 7 (16.3%)
Outcome
Alive and disease free 33 (76.8%)
Alive with disease 6 (13.9%)
Died of disease 4 (9.3%)
Table 2 Relationship between histological grade of tumours, EGFR gene
copy number, EGFR expression and pERK1/2 expression with disease-free
interval (DFI) and overall survival (OS)
Variable DFI OS
Histological grade
3 vs 2+1 P¼0.001 P¼0.001
EGFR gene copy number
Polysomy vs normal P¼0.003 P¼0.019
EGFR protein expression
Positive vs negative P¼0.286 P¼0.307
pERK1/2 expression
Positive vs negative P¼0.004 P¼0.001
Abbreviations: EGFR¼epidermal growth factor receptor; pERK1/2¼activated
extracellular signal-regulated kinases.
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swas associated with neither disease-free interval (P¼0.286) nor
overall survival (P¼0.307).
The pERK1/2 protein was expressed in 34 tumours (79%). There
was a statistical correlation between pERK1/2 positivity and
histological grade of tumour (Po0.001, ANOVA), shorter
disease-free interval (P¼0.004) and overall survival (P¼0.001).
High-pERK1/2 expression (positivity in X30% of neoplastic cells)
was observed in 21 tumours (49%). High-pERK1/2 expression was
associated with shorter overall survival (P¼0.025) (Figure 2), but
not with disease-free interval (P¼0.108). All cases with EGFR
polysomy had high expression of pERK1/2 (P¼0.002) and there
was a marginally significant correlation between high expression of
pERK1/2 and EGFR immunohistochemical expression (P¼0.047)
(Figure 3).
DISCUSSION
This study shows that high-grade MECs with aggressive behaviour
harbour an increased EGFR gene copy number and high
expression of pERK1/2 MAPKs. In spite of the fact that EGFR
amplification was not seen in any of the 43 cases of this series, in
six of them there was high polysomy with X4 EGFR gene copies.
The EGFR gene is rarely amplified in human cancers, but the
increased EGFR gene copy number with balanced chromosome 7
polysomy in cancer cells is relatively frequent, in B24–40% of
patients with non-small cell lung cancer, squamous-cell carcinoma
of the head and neck or colorectal cancer. Chromosome 7
polysomy has been linked to tumour aggressiveness and poor
clinical outcome (Hirsch et al, 2003; Ciardello and Tortora, 2008).
In this study, all cases with EGFR gene gains had a significant
shorter disease-free interval and overall survival. The EGFR
product is a membrane glycoprotein composed of an extracellular
ligand-binding domain, a transmembrane lipophilic component
and an intracellular protein kinase domain. The ligand binding
induces EGFR dimerisation, activation of the intrinsic tyrosine
kinase protein and tyrosine phosphorylation with the activation of
a cascade of biochemical and physiological responses (Lewis et al,
1998). This downstream signalling transduction activates MAPKs
through phosphorylation by MAPK kinases, and the activation of
this pathway is associated with cell proliferation and oncogenic
transformation (Grandis and Sok, 2004). In this series, there was a
significant correlation between increased EGFR copy number and
high expression of pERK1/2 (P¼0.002). High expression of
activated ERK1/2 has been related to tumour progression in
several neoplasms (Albanell et al, 2001; Adeyinka et al, 2002) and
in salivary gland MECs (Handra-Luca et al, 2003). In this series,
the pERK1/2 expression was significantly correlated with shorter
disease-free interval and overall survival. Furthermore, MAPKs can
also be activated through the upstream activation of HER2/neu or
RAS. About one third of salivary gland MECs have HER2/neu gene
amplification (Press et al, 1994) and about one fifth of MECs
harbour H-RAS mutations (Yoo and Robinson, 2000a), but K-RAS
mutations are extremely rare (Yoo and Robinson, 2000b).
However, to define the molecular mechanisms underlying the
biological behaviour in high-grade MECs, in vitro experiments
with cell lines should be carried out.
The immunohistochemical expression of EGFR in the majority
of MECs that we have observed is concordant with other studies
(Gibbons et al, 2001; Shang et al, 2007). All cases with
chromosome 7 polysomy had an expression of EGFR protein of
over 60% of cells. Nevertheless, most immunohistochemical
positive cases failed to show an increased EGFR gene copy
number. This discrepancy between the EGFR gene copy number
and the immunohistochemical detection of the protein has been
reported before in several cancers, and has been attributed to a
post-transcriptional phenomenon mediated at the mRNA level
(Grandis and Tweardy, 1993). There was a significant correlation
between the EGFR protein expression and the histological grade of
the tumours, but not with the clinical outcome of the patients. The
current grading system classification is three-tiered, and tumours
are classified into low-, intermediate- and high-grade MECs,
depending on the architecture and cellular characteristics of the
neoplasms. Low-grade tumours are usually well-defined tumours,
often cystic with a predominance of mucous cells, whereas high-
grade MECs usually have an infiltrative pattern of growth, are solid
and mainly composed of intermediate type and epidermoid cells.
High mitotic index, cellular anaplasia, necrosis and perineural
invasion are characteristics of high-grade tumours (Spiro, 1986;
Kaplan–Meier survival estimates
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Figure 1 Kaplan–Meier curve for overall survival stratified by CISH
results (normal EGFR gene copy number vs increased EGFR gene
copy number).
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Figure 2 Kaplan–Meier curve for overall survival stratified by activated
ERK1/2 expression (low-pERK1/2 expression vs high-pERK1/2 expression).
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sEllis and Auclair, 2008). Significant differences in the outcome
of the patients related to histological grade have been repeatedly
confirmed in series of MECs of the salivary glands (Goode
et al, 1998; Alos et al, 2005; Nance et al, 2008). In this study,
a statistical correlation between the histological grade and
disease-free interval and overall survival of the patients was
found. The prognostic value of the EGFR polysomy, and the
EGFR and the pERK1/2 protein expressions were related to the
histological grade.
Strategies against EGFR include monoclonal antibodies able to
bind to the extracellular domain of the receptor such as cetuximab,
or small molecule ATP-competitive tyrosine kinase inhibitors
(TKIs), such as gefitinib and erlotinib. Some clinical, histopatho-
logical and molecular characteristics have been proposed for
identifying the population sensitive to EGFR-TKI treatment in
non-small carcinoma of the lung (Sone et al, 2007). Activating
mutation in exons 18, 19 and 21 of the EGFR gene has proved to be
a significant factor in predicting response to EGFR-TKIs in non-
small cell carcinoma of the lung. However, these mutations are less
common in the United States and European population than in the
Asian population (Sone et al, 2007), and data from large
randomised studies indicate that increased EGFR gene copy
number is probably the best factor in predicting response and
evaluate overall survival of the patients (Hirsch et al, 2005; Tsao
et al, 2005; Cappuzzo et al, 2005). Interestingly, a good response to
EGFR antagonists in head and neck and lung carcinomas with
expression of MAPKs has been observed (Albanell et al, 2001;
Gandara et al, 2004). Moreover, immunohistochemical positivity
for activated ERK1/2 has been correlated with a good response to
MAPKs inhibitors in clinical trials on cutaneous melanomas
(Jilaveanu et al, 2009). Therefore, the high-grade MECs in this
series, with increased EGFR gene copy number and pERK1/2 high
expression could be sensitive to EGFR or MAPKs antagonists.
The MECs of the lung share histological and molecular
characteristics with salivary gland MECs. Some series on lung
MECs have shown lack of EGFR mutations in these tumours and a
percentage of chromosome 7 polysomy of 17%, similar to the
results in our series (Macarenco et al, 2008). However, some lung
MECs have been described as having activating EGFR mutations
in the Asian population (Han et al, 2008). The MECs and
adenosquamous carcinomas share histological characteristics
and differential diagnosis between both tumour types may be
challenging in the head and neck region and lung (Alos et al, 2004;
Rossi et al, 2009). Adenosquamous carcinomas are aggressive
tumours arising from upper or lower airways, whereas MECs have
a salivary or bronchial gland origin, whose prognosis depends on
the histological grade. Adenosquamous carcinomas usually
harbour EGFR activating mutations, whereas MECs do not (Kang
et al, 2007; Han et al, 2008; Macarenco et al, 2008; Rossi et al,
2009). Previous studies on salivary gland MECs have found that
EGFR mutations are extremely rare (Han et al, 2008; Dahse and
Kosmehl, 2008; Dahse et al, 2009).
To date, few cases on metastatic salivary gland MECs with EGFR
gene gains with chromsome 7 polysomy and good response to
EGFR monoclonal antibody cetuximab have been published
(Grisanti et al, 2008). However, clinical trials that include a large
series of salivary gland MECs are difficult to carry out because of
the low number of these cases in each institution.
In conclusion, we have identified that high-grade salivary gland
MECs usually have an increased EGFR gene copy number and
Figure 3 An example of high-grade mucoepidermoid carcinoma. (A) Histological characteristics of the neoplasm (HE  200). (B) The CISH analysis
shows high polysomy. Four or five signals (both red EGFR and blue centromere) are seen in each nucleus in most of the neoplastic cells (EGFR CISH  630).
(C) Expression of EGFR protein with strong and diffuse membrane positivity (EGFR  400). (D) High expression of activated ERK1/2 with nuclear positivity
in most of the neoplastic cells (pERK1/2  400).
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shighly express pERK1/2. The activation of the EGFR/ERK pathway
in these tumours is associated with aggressive behaviour and could
represent potential indicators of response to EGFR antagonists or
MAPK pathway inhibitors.
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